PMID- 38184452
OWN - NLM
STAT- Publisher
LR  - 20240106
IS  - 1878-0938 (Electronic)
IS  - 1878-0938 (Linking)
DP  - 2023 Dec 27
TI  - Efficacy and safety of post-closure technique using Perclose ProGlide/ProStyle 
      device for large-bore mechanical circulatory support access sites.
LID - S1553-8389(23)00970-3 [pii]
LID - 10.1016/j.carrev.2023.12.016 [doi]
AB  - PURPOSE: Mechanical circulatory support (MCS) using a venoarterial extracorporeal 
      membrane oxygenation (VA-ECMO) device or a catheter-type heart pump (Impella) is 
      critical for the rescue of patients with severe cardiogenic shock. However, these 
      MCS devices require large-bore cannula access (14-Fr and larger) at the femoral 
      artery or vein, which often requires surgical decannulation. METHODS: In this 
      retrospective study, we evaluated post-closure method using a percutaneous 
      suture-mediated vascular closure system, Perclose ProGlide/ProStyle (Abbott 
      Vascular, Lake Bluff, IL, Perclose), as an alternative procedure for MCS 
      decannulation. Closure of 83 Impella access sites and 68 VA-ECMO access sites 
      performed using Perclose or surgical method between January 2018 and March 2023 
      were evaluated. RESULTS: MCS decannulation using Perclose was successfully 
      completed in all access sites without surgical hemostasis. The procedure time of 
      ProGlide was shorter than surgical decannulation for both Impella and VA-ECMO 
      (13 min vs. 50 min; p < 0.001, 21 min vs. 65 min; p < 0.001, respectively). There 
      were no significant differences in the 30-day survival rate and major adverse 
      events by decannulation including arterial dissection requiring endovascular 
      treatment, hemorrhage requiring a large amount of red blood cell transfusion, and 
      access site infection. CONCLUSION: Our results suggest that the post-closure 
      technique using the percutaneous suture-mediated closure system appears to be a 
      safe and effective method for large-bore MCS decannulation.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Unoki, Takashi
AU  - Unoki T
AD  - Intensive Care Unit, Saiseikai Kumamoto Hospital, Kumamoto, Japan; Department of 
      Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka, 
      Japan. Electronic address: tunoki@hotmail.co.jp.
FAU - Konami, Yutaka
AU  - Konami Y
AD  - Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, 
      Kumamoto, Japan.
FAU - Nakayama, Tomoko
AU  - Nakayama T
AD  - Intensive Care Unit, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
FAU - Suzuyama, Hiroto
AU  - Suzuyama H
AD  - Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, 
      Kumamoto, Japan.
FAU - Horio, Eiji
AU  - Horio E
AD  - Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, 
      Kumamoto, Japan.
FAU - Taguchi, Eiji
AU  - Taguchi E
AD  - Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, 
      Kumamoto, Japan.
FAU - Saku, Keita
AU  - Saku K
AD  - Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular 
      Center, Osaka, Japan.
FAU - Sawamura, Tadashi
AU  - Sawamura T
AD  - Intensive Care Unit, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
FAU - Nakao, Koichi
AU  - Nakao K
AD  - Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, 
      Kumamoto, Japan.
FAU - Sakamoto, Tomohiro
AU  - Sakamoto T
AD  - Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, 
      Kumamoto, Japan.
LA  - eng
PT  - Journal Article
DEP - 20231227
PL  - United States
TA  - Cardiovasc Revasc Med
JT  - Cardiovascular revascularization medicine : including molecular interventions
JID - 101238551
SB  - IM
OTO - NOTNLM
OT  - Impella
OT  - Large-bore decannulation
OT  - Mechanical circulatory support
OT  - Percutaneous suture-mediated vascular closure device
COIS- Declaration of competing interest Keita Saku received research funding from Omron 
      Healthcare Co., Abiomed Japan K.K., NTT Research, Inc., Asahi Kasei ZOLL Medical 
      Corporation, Neuroceuticals Inc., and Zeon Medical Inc., and honoraria from 
      Abiomed Japan K.K., Ono Pharmaceutical Co., Ltd., and Mallinckrodt Japan Co. Ltd. 
      The other authors declare no conflict of interest.
EDAT- 2024/01/07 06:44
MHDA- 2024/01/07 06:44
CRDT- 2024/01/06 21:56
PHST- 2023/06/10 00:00 [received]
PHST- 2023/11/06 00:00 [revised]
PHST- 2023/12/21 00:00 [accepted]
PHST- 2024/01/07 06:44 [medline]
PHST- 2024/01/07 06:44 [pubmed]
PHST- 2024/01/06 21:56 [entrez]
AID - S1553-8389(23)00970-3 [pii]
AID - 10.1016/j.carrev.2023.12.016 [doi]
PST - aheadofprint
SO  - Cardiovasc Revasc Med. 2023 Dec 27:S1553-8389(23)00970-3. doi: 
      10.1016/j.carrev.2023.12.016.